1453 PD-L1 testing for access to pembrolizumab in patients with unresectable mesothelioma

Page last updated: 24 November 2016

Application Detail



Description of Medical Service

ImmunoHistoChemistry (IHC) test for evaluation of Programmed Cell Death Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab

Description of Medical Condition

unresectable mesothelioma

Reason for Application

New MBS item

Medical Service Type

Co-dependent technology

Previous Application Number

Not Applicable

Associated Documentation

Application Form

Application form (PDF 247 KB)
Application form (Word 536 KB)

PICO Confirmation

PICO Confirmation (PDF 725 KB)
PICO Confirmation (Word 210 KB)

Assessment Report


Public Summary Document


Meetings for this Application


8 December 2016